Defining the Pathogenesis of Immune Deficiency in Chronic HIV Infection
定义慢性 HIV 感染免疫缺陷的发病机制
基本信息
- 批准号:8303401
- 负责人:
- 金额:$ 191.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-08-01 至 2014-07-31
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAgonistApoptosisAttenuatedBacterial RNABloodC-Type LectinsCD4 Positive T LymphocytesCD8B1 geneCanadaCell Cycle ProgressionCellsCercocebus atysCessation of lifeCharacteristicsChargeChronicClinicalDNADataDiseaseDoctor of MedicineDoctor of PhilosophyEffector CellEnvironmentExperimental Animal ModelExposure toFunctional disorderGene ExpressionHIVHIV InfectionsImmuneImmune System DiseasesImmune systemIn SituInfectionInstitutionInterleukin 2 Receptor GammaInterleukin-15Interleukin-2Intestinal MucosaIntestinesLaboratory ResearchLigandsLymphocyteLymphoid TissueMacaca mulattaMemoryModelingPathogenesisPathway interactionsPatternPennsylvaniaPeripheral Blood Mononuclear CellPersonsPhosphorylationPlasmaReagentResearchResearch PersonnelResistanceResourcesRoleSIVSeriesSignal TransductionSiteSpecimenSphingosine-1-Phosphate ReceptorSurfaceSuspension substanceSuspensionsT memory cellT-Cell ActivationT-Cell DepletionT-LymphocyteTLR7 geneTestingTissuesUnited Statesbasecytokinedesignexperienceimmune activationin vitro Modellymph nodesmembermemory CD4 T lymphocytemicrobialnonhuman primateprogramsresearch studyskills
项目摘要
DESCRIPTION (provided by applicant): This program project application is submitted by the members of the Cleveland Immunopathogenesis Consortium (CLIC) a group of investigators representing 10 academic and research institutions in the United States and Canada who have engaged for more than three years in a coordinated research effort aimed at unraveling the mechanisms whereby HIV infection results in progressive immune deficiency. This group of experienced, outstanding investigators capitalizes on complementary research skills and resources and proposes an interdisciplinary program comprising 4 projects that are coordinated and supported by two cores: Administrative Core, charged with overall coordination and administration of the program and Specimen Acquisition Core, Alan Landay, PI, charged with assuring a sustained supply of clinical specimens of gut and lymph nodes to support project investigators. The projects comprise a series of interacting research platforms from basic laboratory research to experimental animal models to translational projects, each designed to explore the determinants and mechanisms whereby immune activation drives CD4+ T cell depletion and dysfunction in chronic HIV infection. Project #1: Bystander activation drives T cell losses in chronic HIV infection - PIs: Michael M. Lederman, M.D., Scott F. Sieg Ph.D. - Case, will test the hypothesis that increased systemic levels of microbial TLR ligands and common gamma chain cytokines in secondary lymphoid tissues drive central memory T cell activation and turnover in chronic HIV infection. Project #2: Loss of intestinal barrier function in HIV infection - Alan Levine, Ph.D. Case, will examine the integrity of the intestinal mucosa in HIV infection to document the mechanistic details underlying the enhanced translocation of microbial products through the damaged gut that we propose contributes to the pathogenesis of cell loss in chronic HIV infection. Project #3: Immune activation and AIDS pathogenesis in SIV-infected non-human primates - Guido Silvestri, M.D., Univ of Pennsylvania, will attempt to induce disease in non-pathogenic SIV infection of sooty mangabeys by activation of the innate immune system and will test whether blocking innate immune activation will attenuate disease pathogenesis in infected rhesus macaques. Project #4: Immune activation promotes PD1 expression and immune dysfunction in chronic HIV infection - Rafick Pierre Sekaly Ph.D. - Univ of Montreal, will examine the role of innate immune system activation through the interaction between HIV RNAs and TLR7/8 on the expression of PDL-1 and 2 and their effects on the function and survival of HIV reactive T cells.
该项目申请由克利夫兰免疫病理学联盟(CLIC)的成员提交,该联盟是一组代表美国和加拿大10个学术和研究机构的研究人员,他们从事了三年多的协调研究工作,旨在揭示HIV感染导致进行性免疫缺陷的机制。这组经验丰富,优秀的研究人员利用互补的研究技能和资源,并提出了一个跨学科的计划,包括由两个核心协调和支持的4个项目:行政核心,负责项目和标本采集核心的总体协调和管理,Alan Landay,PI,负责确保肠道和淋巴结临床标本的持续供应,以支持项目研究人员。这些项目包括一系列相互作用的研究平台,从基础实验室研究到实验动物模型再到转化项目,每个项目都旨在探索免疫激活驱动慢性HIV感染中CD 4 + T细胞耗竭和功能障碍的决定因素和机制。项目#1:旁观者激活驱动慢性HIV感染中的T细胞损失-PI:Michael M.莱德曼,医学博士,斯科特·F Sieg博士- Case将检验以下假设:次级淋巴组织中微生物TLR配体和常见γ链细胞因子的全身水平增加会驱动慢性HIV感染中的中央记忆T细胞激活和更替。项目#2:HIV感染中肠道屏障功能的丧失- Alan Levine博士病例,将检查HIV感染中肠粘膜的完整性,以记录微生物产物通过受损肠道的增强易位的机制细节,我们提出这有助于慢性HIV感染中细胞丢失的发病机制。项目#3:SIV感染的非人灵长类动物的免疫激活和艾滋病发病机制- Guido Silvestri,医学博士,宾夕法尼亚大学,将尝试通过激活先天免疫系统在非致病性SIV感染的白眉猴中诱导疾病,并将测试阻断先天免疫激活是否会减弱受感染恒河猴的疾病发病机制。项目#4:免疫激活促进慢性HIV感染中的PD 1表达和免疫功能障碍- Rafick Pierre Sekaly博士- 蒙特利尔大学,将通过HIV RNA和TLR 7/8对PDL-1和2表达的相互作用及其对HIV反应性T细胞功能和存活的影响来研究先天免疫系统激活的作用。
项目成果
期刊论文数量(14)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Compromised gastrointestinal integrity in pigtail macaques is associated with increased microbial translocation, immune activation, and IL-17 production in the absence of SIV infection.
- DOI:10.1038/mi.2010.14
- 发表时间:2010-07
- 期刊:
- 影响因子:8
- 作者:
- 通讯作者:
Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection.
- DOI:10.1038/nm.2106
- 发表时间:2010-04
- 期刊:
- 影响因子:82.9
- 作者:
- 通讯作者:
PD-1 coinhibitory signals: the link between pathogenesis and protection.
- DOI:10.1016/j.smim.2013.02.002
- 发表时间:2013-10-31
- 期刊:
- 影响因子:7.8
- 作者:Kulpa DA;Lawani M;Cooper A;Peretz Y;Ahlers J;Sékaly RP
- 通讯作者:Sékaly RP
Lipopolysaccharide and soluble CD14 in cord blood plasma are associated with prematurity and chorioamnionitis.
- DOI:10.1038/pr.2013.182
- 发表时间:2014-01
- 期刊:
- 影响因子:3.6
- 作者:Martinez-Lopez, Denise G.;Funderburg, Nicholas T.;Cerissi, Adam;Rifaie, Reema;Aviles-Medina, Laura;Llorens-Bonilla, Braulio J.;Sleasman, John;Luciano, Angel A.
- 通讯作者:Luciano, Angel A.
Dissecting the HIV-specific immune response: a systems biology approach.
- DOI:10.1097/coh.0b013e32834ddb0e
- 发表时间:2012-01
- 期刊:
- 影响因子:4.1
- 作者:Peretz Y;Cameron C;Sékaly RP
- 通讯作者:Sékaly RP
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL MARCEL LEDERMAN其他文献
MICHAEL MARCEL LEDERMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL MARCEL LEDERMAN', 18)}}的其他基金
Targeting Cytolytic Cells to Lymphoid Sites of HIV Persistence.
将溶细胞细胞靶向 HIV 持续存在的淋巴部位。
- 批准号:
9292706 - 财政年份:2016
- 资助金额:
$ 191.27万 - 项目类别:
Targeting Cytolytic Cells to Lymphoid Sites of HIV Persistence.
将溶细胞细胞靶向 HIV 持续存在的淋巴部位。
- 批准号:
8841193 - 财政年份:2014
- 资助金额:
$ 191.27万 - 项目类别:
Targeting Cytolytic Cells to Lymphoid Sites of HIV Persistence.
将溶细胞细胞靶向 HIV 持续存在的淋巴部位。
- 批准号:
8930055 - 财政年份:2014
- 资助金额:
$ 191.27万 - 项目类别:
Effects of IL-6 blockade in treated HIV infection
IL-6 阻断对 HIV 感染治疗的影响
- 批准号:
8617799 - 财政年份:2013
- 资助金额:
$ 191.27万 - 项目类别:
Effects of IL-6 blockade in treated HIV infection
IL-6 阻断对 HIV 感染治疗的影响
- 批准号:
9005805 - 财政年份:2013
- 资助金额:
$ 191.27万 - 项目类别:
Effects of IL-6 blockade in treated HIV infection
IL-6 阻断对 HIV 感染治疗的影响
- 批准号:
8510992 - 财政年份:2013
- 资助金额:
$ 191.27万 - 项目类别:
Basic and Comparative Studies of CCR5 Inhibition to Prevent HIV Transmission
抑制 CCR5 预防 HIV 传播的基础和比较研究
- 批准号:
7391001 - 财政年份:2008
- 资助金额:
$ 191.27万 - 项目类别:
Defining the Pathogenesis of Immune Deficiency in Chronic HIV Infection
定义慢性 HIV 感染免疫缺陷的发病机制
- 批准号:
8115015 - 财政年份:2008
- 资助金额:
$ 191.27万 - 项目类别:
Developing RANTES analogues as topical strategies to prevent HIV transmission
开发 RANTES 类似物作为预防 HIV 传播的局部策略
- 批准号:
7418081 - 财政年份:2008
- 资助金额:
$ 191.27万 - 项目类别:
Defining the Pathogenesis of Immune Deficiency in Chronic HIV Infection
定义慢性 HIV 感染免疫缺陷的发病机制
- 批准号:
7666054 - 财政年份:2008
- 资助金额:
$ 191.27万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 191.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 191.27万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 191.27万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 191.27万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 191.27万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 191.27万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 191.27万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 191.27万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 191.27万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 191.27万 - 项目类别: